KEY DETAILS
STAT News reports a new trial, announced Oct. 13, 2026, will enroll up to 1,200 people with alcohol use disorder, opioid use disorder, or both, starting early 2027.
Yahoo Finance reports Eli Lilly's TOGETHER PsO data pairing Taltz with Zepbound highlight a potential immunometabolic link between psoriasis and obesity.
MedPage Today reported on Oct. 13, 2026 that Novo Nordisk announced plans to discontinue its liraglutide injectable Saxenda in early 2027 due to declining sales.
MedPage Today reported on Oct. 13, 2026 that the World Health Organization announced its first obesity guidelines for children and adolescents, recommending against using weight-loss drugs or bariatric surgery in patients younger than 10 years of age.
Fool.com reports patients on tirzepatide plus eloralintide lost up to 23.3% of their weight versus 14.8% on tirzepatide alone after 48 weeks, with a discontinuation rate as high as 27%.
STAT News reports that a new trial, announced on Oct. 13, 2026, will enroll up to 1,200 people with alcohol use disorder, opioid use disorder, or both, starting early 2027. Change is coming to another product too. MedPage Today reported on Oct. 13 that Novo Nordisk announced plans to discontinue its liraglutide injectable Saxenda in early 2027 due to declining sales. Fool.com reports a drug combination with tirzepatide produced more weight loss than tirzepatide alone in a trial, though discontinuation was also higher.
STAT News reports that a new trial, announced on Oct. 13, 2026, will test the real-world impacts of weekly semaglutide injections, focusing on factors like a person's involvement with the criminal justice system, employment, housing stability, and health care utilization. The study, set to begin in early 2027, will enroll up to 1,200 participants with alcohol use disorder, opioid use disorder, or both, according to STAT News. STAT News also reports that a wave of clinical trials have begun to test the ability of GLP-1 weight loss drugs to quell various substance use disorders, with some promising results.
Attention also turned to a different kind of connection inside one company's own data. Yahoo Finance reported on Oct. 13, 2026 that Eli Lilly's TOGETHER PsO data pairing Taltz with Zepbound highlight a potential immunometabolic link between psoriasis and obesity. According to Yahoo Finance, the data strengthens the idea that cardiometabolic and immunology assets can work together, though it does not materially change the near-term focus on obesity and diabetes volumes or the key risk around GLP-1 pricing pressure and litigation exposure. Yahoo Finance also reports that one narrative about Lilly projects $118.9 billion in revenue and $50.1 billion in earnings by 2029, with some analysts assuming figures closer to $139 billion in revenue and $56 billion in earnings.
There's a product update worth noting as well. MedPage Today reported on Oct. 13, 2026 that Novo Nordisk announced plans to discontinue its liraglutide injectable Saxenda in early 2027 due to declining sales.
A guideline announcement also appeared in the same MedPage Today report from Oct. 13, 2026. MedPage Today reports that the World Health Organization announced its first obesity guidelines for children and adolescents, recommending against using weight-loss drugs or bariatric surgery in patients younger than 10 years of age.
Trial results reported by Fool.com on Oct. 12, 2026 point to a tradeoff between effect and tolerability. Fool.com reports that patients taking tirzepatide together with eloralintide, an experimental drug that targets the hormone amylin but not GLP-1, lost up to 23.3% of their weight after 48 weeks, compared with 14.8% for those on tirzepatide alone. The same report notes the discontinuation rate was as high as 27%, which Fool.com suggests may point to tolerability concerns.
You can find the full reporting at STAT News, Yahoo Finance, MedPage Today, and Fool.com. Each outlet has more detail than fits in one roundup.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.